Evidence map›Paper›PMID 16940533›Full record

ArticleJournal of virology2006

Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Donald N Forthal, Gary Landucci, Kelly Stefano Cole, Marta Marthas, Juan C Becerra, Koen Van Rompay

Abstract read
In one paragraph

Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope.Molecular therapy : the journal of the American Society of Gene Therapy · 2019
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Donald N ForthalDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of California-Irvine, Irvine, CA 92697-4028, USA. dnfortha@uci.edu
Gary Landucci
Kelly Stefano Cole
Marta Marthas
Juan C Becerra
Koen Van Rompay

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
Novel Biological Activities of Anti-Viral AntibodyR01AI052039 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N · 2002 to 2006
$1.5M
DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATIONR01AI047758 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MONTELARO, RONALD C · 2000 to 2004
$1.3M
Mechanisms of SIV NeutralizationR01AI052058 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COLE, KELLY STEFANO · 2002 to 2005
$1.2M
NCRR NIH HHS P51 RR000169NCRR NIH HHS RR 00169NIAID NIH HHS AI 52039NIAID NIH HHS R01 AI052039NIAID NIH HHS R01 AI052058NIAID NIH HHS R01 AI 52058
6 · The paper itself

Abstract

Although antibodies can prevent or modulate lentivirus infections in nonhuman primates, the biological functions of antibody responsible for such effects are not known. We sought to determine the role of antibody-dependent cell-mediated virus inhibition (ADCVI), an antibody function that inhibits virus yield from infected cells in the presence of Fc receptor-bearing effector cells, in preventing or controlling SIVmac251 infection in rhesus macaques (Macaca mulatta). Using CEMx174 cells infected with simian immunodeficiency virus mac251 (SIVmac251), both polyclonal and monoclonal anti-SIV antibodies were capable of potent virus inhibition in the presence of human peripheral blood mononuclear cell (PBMC) effector cells. In the absence of effector cells, virus inhibition was generally very poor. PBMCs from healthy rhesus macaques were also capable of mediating virus inhibition either against SIVmac251-infected CEMx174 cells or against infected, autologous rhesus target cells. We identified both CD14(+) cells and, to a lesser extent, CD8(+) cells as the effector cell population in the rhesus PBMCs. Finally, pooled, nonneutralizing SIV-antibody-positive serum, shown in a previous study to prevent infection of neonatal macaques after oral SIVmac251 challenge, had potent virus-inhibitory activity in the presence of effector cells; intact immunoglobulin G, rather than F(ab')(2), was required for such activity. This is the first demonstration of both humoral and cellular ADCVI functions in the macaque-SIV model. ADCVI activity in nonneutralizing serum that prevents SIV infection suggests that ADCVI may be a protective immune function. Finally, our data underscore the potential importance of Fc-Fc receptor interactions in mediating biological activities of antibody.

Indexed as

AnimalsAntibodies, MonoclonalCD8-Positive T-LymphocytesHumansImmunoglobulin FragmentsImmunoglobulin GLeukocytes, MononuclearLipopolysaccharide ReceptorsMacaca mulattaReceptors, FcSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAntibodies, MonoclonalImmunoglobulin FragmentsImmunoglobulin GLipopolysaccharide ReceptorsReceptors, Fc

Identifiers

PMID16940533
PMCPMC1563916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.